Locations:
SearchAdvertisement
New study examines rates of downgrading in patients with aggressive prostate cancer
Clinical indications, how it's filling a void in diagnostic care and more
This cell surface protein could be an immune checkpoint inhibition target
Test can identify aggressive vs. indolent disease, reduce unneeded biopsies
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
The short answer from the front line of prostate cancer screening
Early results presented at ASCO 2018
Insight into the biology and future behavior of prostate tumors
Negative affect reported in several sexuality-related functions at two years
Milestone studies advance understanding and treatment of prostate cancer
Investigators looked at nearly 3 million patients
Advertisement
Advertisement